HEALTH● LOWJun 24 · Jun 24, 2026, 8:15 AM
H . Lundbeck A / S : Lundbeck presents new Vyepti ( eptinezumab ) and bocunebart migraine portfolio data at EAN 2026
finanznachrichten.de · Germany
H. Lundbeck A/S has presented new data regarding its Vyepti (eptinezumab) and bocunebart migraine treatments at the EAN 2026 event. This highlights ongoing developments in migraine therapy.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More from Germany
MILITARY4h agoFrom tanks to space, Norway and Germany forge ahead with ‘Hansa’ defense pactDefense NewsPOLITICS5h agoToo big to ban? Germany wrestles with outlawing its most popular partyIrish Times WorldPOLITICS5h agoGermany news: Merz hopes for Korean reunification at DMZDW News [en]POLITICS5h agoGermany news: Merz calls for Korean reunification at DMZDW News [en]
More in Health
HEALTH8m agoNIPRD records gains in research, staff welfare, public healthPremium TimesHEALTH1h agoZamfara Confirms 38 Cases Of Strange Illness In Two LGAsChannels TVHEALTH1h agoDay Center and Addiction Rehabilitation in a historic area of San JuanClarínHEALTH1h agoEbola outbreak not under control in Africa, CDC warnsVanguard Nigeria